About Neptune Technologies & Bioressources (NASDAQ:NEPT)
Neptune Technologies & Bioressources Inc. is a solution provider of omega-3's and other functional ingredients to branded marketers in the nutraceutical industry, primarily in North America. The Company is engaged in the development, manufacture and commercialization of marine-derived omega-3 fatty acids. The Company's products include Krill-Based Nutraceutical Products, including Neptune Krill Oil (NKO), OCEANO3, Formulations Derived from NKO and Neptune Krill Aquatein (NKA); Other Nutraceutical Products, and Pharmaceutical Product Candidate (CaPre)-Acasti. The Company's NKO is a marine oil extracted from krill (Euphasia superba). NKO consists of phospholipids, which contain omega-3 fatty acids, including eicosapentaenoic acid and docosahexaenoic acid (EPA & DHA), and antioxidants, such as astaxanthin, vitamin A and vitamin E. The Company sells OCEANO3 directly to consumers in Canada through its online platform (www.oceano3.com), under its brand name.
Industry, Sector and Symbol
Industry Biotechnology & Medical Research
Trailing P/E Ratio37.63
Forward P/E RatioN/A
Sales & Book Value
Annual Sales$17.36 million
Price / Sales13.66
Price / CashN/A
Book Value$0.66 per share
Price / Book4.56
Return on EquityN/A
Return on AssetsN/A
Neptune Technologies & Bioressources (NASDAQ:NEPT) Frequently Asked Questions
What is Neptune Technologies & Bioressources' stock symbol?
Neptune Technologies & Bioressources trades on the NASDAQ under the ticker symbol "NEPT."
How were Neptune Technologies & Bioressources' earnings last quarter?
Neptune Technologies & Bioressources-Ord (NASDAQ:NEPT) issued its quarterly earnings data on Wednesday, October, 12th. The biotechnology company reported ($0.02) earnings per share (EPS) for the quarter. The biotechnology company had revenue of $8.91 million for the quarter. View Neptune Technologies & Bioressources' Earnings History.
Who are some of Neptune Technologies & Bioressources' key competitors?
Some companies that are related to Neptune Technologies & Bioressources include Cara Therapeutics (CARA), Agenus (AGEN), Codexis (CDXS), Celyad (CYAD), Puretech Health (PRTC), PDL BioPharma (PDLI), Inovio Pharmaceuticals (INO), Idera Pharmaceuticals (IDRA), Protagonist Therapeutics (PTGX), GTX (GTXI), Protalix Biotherapeutics (PLX), Celldex Therapeutics (CLDX), Arbutus Biopharma (ABUS), Horizon Discovery Group (HZD), Chromadex (CDXC), NewLink Genetics (NLNK), Cellular Dynamics International (ICEL) and CASI Pharmaceuticals (CASI).
Who are Neptune Technologies & Bioressources' key executives?
Neptune Technologies & Bioressources' management team includes the folowing people:
- John Moretz, Chairman of the Board
- James Stuart Hamilton, President, Chief Executive Officer, Director
- Mario Paradis, Chief Financial Officer
- Michel Timperio, Senior Vice President of Sales - Global Sales
- Pierre Lemieux Ph.D., Chief Operating Officer of Acasti
- Jean-Daniel Belanger, Corporate Secretary and Director - Corporate Affairs
- Harlan W. Waksal M.D., Director (Age 61)
- Valier Boivin, Independent Director
- Ronald Denis, Independent Director
- Adrian Taylor Montgomery, Independent Director
Who owns Neptune Technologies & Bioressources stock?
Neptune Technologies & Bioressources' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Perceptive Advisors LLC (10.65%),
PERCEPTIVE ADVISORS LLC
PERCEPTIVE ADVISORS LLC
(10.20%), Deutsche Bank AG (0.24%) and Virtu Financial LLC (0.22%). View Institutional Ownership Trends for Neptune Technologies & Bioressources.
Who bought Neptune Technologies & Bioressources stock? Who is buying Neptune Technologies & Bioressources stock?
How do I buy Neptune Technologies & Bioressources stock?
Shares of Neptune Technologies & Bioressources can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Neptune Technologies & Bioressources' stock price today?
One share of Neptune Technologies & Bioressources stock can currently be purchased for approximately $3.01.
How big of a company is Neptune Technologies & Bioressources?
Neptune Technologies & Bioressources has a market capitalization of $237.20 million and generates $17.36 million in revenue each year. The biotechnology company earns $-5,730,000.00 in net income (profit) each year or $0.08 on an earnings per share basis.
How can I contact Neptune Technologies & Bioressources?
Neptune Technologies & Bioressources' mailing address is 545 PROMENADE DU CENTROPOLIS SUITE 100, LAVAL A8, H7T 0A3. The biotechnology company can be reached via phone at 45-0687-2262 or via email at [email protected]
MarketBeat Community Rating for Neptune Technologies & Bioressources (NEPT)MarketBeat's community ratings are surveys of what our community members think about Neptune Technologies & Bioressources and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Neptune Technologies & Bioressources (NASDAQ:NEPT) Analyst Ratings History
No equities research coverage for this company has been tracked by MarketBeat
Neptune Technologies & Bioressources (NASDAQ:NEPT) Earnings History and Estimates Chart
Neptune Technologies & Bioressources (NASDAQ NEPT) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|10/12/2016||Q2 2017||($0.02)||$8.91 million||View||N/A|
|7/11/2016||Q1 2017||($0.02)||$8.66 million||View||N/A|
|5/25/2016||Q4 2016||$0.01||$7.20 million||View||N/A|
|1/12/2016||Q3 2016||($0.02)||$4.18 million||View||N/A|
|10/14/2015||Q2 2016||($0.02)||$3.43 million||View||N/A|
|7/13/2015||Q1 2016||($0.05)||$2.18 million||View||N/A|
|5/27/2015||Q4 2015||($0.10)||$3.25 million||View||N/A|
|1/13/2015||Q413||($0.14)||($0.05)||$5.06 million||$3.98 million||View||N/A|
|10/14/2014||Q2 2015||($0.11)||($0.15)||$4.19 million||$2.34 million||View||N/A|
|7/15/2014||Q1 2015||($0.08)||($0.06)||$6.71 million||$3.44 million||View||N/A|
|5/21/2014||Q4 2014||($0.08)||($0.07)||$5.84 million||$3.37 million||View||N/A|
|1/14/2014||Nov 2013||($0.09)||$4.03 million||View||N/A|
|10/15/2013||Q2 2014||($0.06)||$5.16 million||View||N/A|
|7/15/2013||Q1 2014||($0.07)||$5.86 million||View||N/A|
|5/22/2013||Q4 2013||($0.01)||$4.45 million||View||N/A|
|1/15/2013||Q313||($0.18)||$5.12 million||$6.60 million||View||N/A|
Neptune Technologies & Bioressources (NASDAQ:NEPT) Earnings Estimates
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Neptune Technologies & Bioressources (NASDAQ:NEPT)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for Neptune Technologies & Bioressources (NASDAQ NEPT)
No insider trades for this company have been tracked by MarketBeat.com
Neptune Technologies & Bioressources (NASDAQ NEPT) News Headlines
Neptune Technologies & Bioressources (NASDAQ:NEPT) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Neptune Technologies & Bioressources (NASDAQ:NEPT) Income Statement, Balance Sheet and Cash Flow Statement
Neptune Technologies & Bioressources (NASDAQ NEPT) Stock Chart for Tuesday, February, 20, 2018